Tejus Satish1, Rohit Raghunathan2, Jake G Prigoff3, Jason D Wright2,4, Grace A Hillyer5, Meghna S Trivedi2,6, Kevin Kalinsky7, Katherine D Crew2,5,6, Dawn L Hershman2,5,6, Melissa K Accordino2,6. 1. Roy and Diana Vagelos College of Physicians and Surgeons, New York, NY. 2. Herbert Irving Comprehensive Cancer Center, New York, NY. 3. Department of Surgery, Columbia University Irving Medical Center, New York, NY. 4. Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY. 5. Department of Epidemiology, Mailman School of Public Health, New York, NY. 6. Department of Medicine, Columbia University Irving Medical Center, New York NY. 7. Winship Cancer Institute at Emory University, Atlanta, GA.
Abstract
PURPOSE: COVID-19 has altered healthcare delivery. Previous work has focused on patients with cancer and COVID-19, but little has been reported on healthcare system changes among patients without COVID-19. METHODS: We performed a retrospective study of patients with breast cancer (BC) in New York City between February 1, 2020, and April 30, 2020. New patients were included as were patients scheduled to receive intravenous or injectable therapy. Patients with COVID-19 were excluded. Demographic and treatment information were obtained by chart review. Delays and/or changes in systemic therapy, surgery, radiation, and radiology related to the pandemic were tracked, along with the reasons for delay and/or change. Univariate and multivariable analysis were used to identify factors associated with delay and/or change. RESULTS: We identified 350 eligible patients, of whom 149 (42.6%) experienced a delay and/or change, and practice reduction (51.0%) was the most common reason. The patients who identified as Black or African American, Asian, or Other races were more likely to experience a delay and/or change compared with White patients (Black, 44.4%; Asian, 47.1%; Other, 55.6%; White, 31.4%; P = .001). In multivariable analysis, Medicaid compared with commercial insurance (odds ratio [OR], 3.04; 95% CI, 1.32 to 7.27) was associated with increased odds of a delay and/or change, whereas stage II or III BC compared with stage I (OR, 0.38; 95% CI, 0.15 to 0.95; and OR, 0.28; 95% CI, 0.08 to 0.092, respectively) was associated with decreased odds of a delay and/or change. CONCLUSION: Almost half of the patients with BC without COVID-19 had a delay and/or change. We found racial and socioeconomic disparities in the likelihood of a delay and/or change. Further studies are needed to determine the impact these care alterations have on BC outcomes.
PURPOSE:COVID-19 has altered healthcare delivery. Previous work has focused on patients with cancer and COVID-19, but little has been reported on healthcare system changes among patients without COVID-19. METHODS: We performed a retrospective study of patients with breast cancer (BC) in New York City between February 1, 2020, and April 30, 2020. New patients were included as were patients scheduled to receive intravenous or injectable therapy. Patients with COVID-19 were excluded. Demographic and treatment information were obtained by chart review. Delays and/or changes in systemic therapy, surgery, radiation, and radiology related to the pandemic were tracked, along with the reasons for delay and/or change. Univariate and multivariable analysis were used to identify factors associated with delay and/or change. RESULTS: We identified 350 eligible patients, of whom 149 (42.6%) experienced a delay and/or change, and practice reduction (51.0%) was the most common reason. The patients who identified as Black or African American, Asian, or Other races were more likely to experience a delay and/or change compared with White patients (Black, 44.4%; Asian, 47.1%; Other, 55.6%; White, 31.4%; P = .001). In multivariable analysis, Medicaid compared with commercial insurance (odds ratio [OR], 3.04; 95% CI, 1.32 to 7.27) was associated with increased odds of a delay and/or change, whereas stage II or III BC compared with stage I (OR, 0.38; 95% CI, 0.15 to 0.95; and OR, 0.28; 95% CI, 0.08 to 0.092, respectively) was associated with decreased odds of a delay and/or change. CONCLUSION: Almost half of the patients with BC without COVID-19 had a delay and/or change. We found racial and socioeconomic disparities in the likelihood of a delay and/or change. Further studies are needed to determine the impact these care alterations have on BC outcomes.
Authors: Olga Lyudovyk; Justin Y Kim; David Qualls; Madeline A Hwee; Ya-Hui Lin; Sawsan R Boutemine; Yuval Elhanati; Alexander Solovyov; Melanie Douglas; Eunise Chen; N Esther Babady; Lakshmi Ramanathan; Pallavi Vedantam; Chaitanya Bandlamudi; Sigrid Gouma; Philip Wong; Scott E Hensley; Benjamin Greenbaum; Alexander C Huang; Santosha A Vardhana Journal: Cancer Cell Date: 2022-05-30 Impact factor: 38.585
Authors: Jennifer L Caswell-Jin; Maryam N Shafaee; Melissa L Bondy; Allison W Kurian; Lan Xiao; Mina Liu; Esther M John Journal: Breast Cancer Res Treat Date: 2022-05-27 Impact factor: 4.624
Authors: Annie Tang; Elad Neeman; Brooke Vuong; Vignesh A Arasu; Raymond Liu; Gillian E Kuehner; Alison C Savitz; Liisa L Lyon; Prachi Anshu; Samantha A Seaward; Milan D Patel; Laurel A Habel; Lawrence H Kushi; Margaret Mentakis; Eva S Thomas; Tatjana Kolevska; Sharon B Chang Journal: Breast Cancer Res Treat Date: 2022-01-06 Impact factor: 4.624
Authors: Dieuwke R Mink van der Molen; Claudia A Bargon; Marilot C T Batenburg; Lilianne E van Stam; Iris E van Dam; Inge O Baas; Miranda F Ernst; Wiesje Maarse; Maartje Sier; Ernst J P Schoenmaeckers; Thijs van Dalen; Rhodé M Bijlsma; Annemiek Doeksen; Femke van der Leij; Danny A Young-Afat; Helena M Verkooijen Journal: Breast Cancer Res Treat Date: 2021-12-01 Impact factor: 4.624
Authors: Ravi B Parikh; Samuel U Takvorian; Daniel Vader; E Paul Wileyto; Amy S Clark; Daniel J Lee; Gaurav Goyal; Gabrielle B Rocque; Efrat Dotan; Daniel M Geynisman; Pooja Phull; Philippe E Spiess; Roger Y Kim; Amy J Davidoff; Cary P Gross; Natalia Neparidze; Rebecca A Miksad; Gregory S Calip; Caleb M Hearn; Will Ferrell; Lawrence N Shulman; Ronac Mamtani; Rebecca A Hubbard Journal: J Natl Cancer Inst Date: 2022-04-11 Impact factor: 11.816
Authors: Manali I Patel; Jacqueline M Ferguson; Eida Castro; Cristina D Pereira-Estremera; Guillermo N Armaiz-Peña; Ysabel Duron; Fay Hlubocky; Analynn Infantado; Bles Nuqui; Donna Julian; Nii Nortey; Alexandra Steck; Melissa Bondy; Shail Maingi Journal: JAMA Netw Open Date: 2022-07-01